Personalis shares rose after the company received Medicare coverage for its NeXT Personal molecular residual disease test for surveillance of patients with Stage I to III non-small cell lung cancer.

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

After an unforgettable end to the 2025 season, the Circuit Ricardo Tormo plays host to a crucial one-day Valencia Test. It’s the first opportunity for the riders to try some fresh parts and our first ...

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for ...

The Python Software Foundation has rejected a $1.5 million government grant because of anti-DEI requirements imposed by the Trump administration, the nonprofit said in a blog post yesterday. The grant ...

They look, move and even smell like the kind of furry Everglades marsh rabbit a Burmese python would love to eat. But these bunnies are robots meant to lure the giant invasive snakes out of their ...

Traditional Medicare will face greater use of prior authorizations under a pilot program by the Centers for Medicare & Medicaid Services, potentially eroding one area that enrollees like about their ...

Indiana is facing a growing challenge in funding Applied Behavior Analysis (ABA) therapy for individuals with autism, and the state is now turning to families, providers, and community members for ...

NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc.

A blood test that could scan for dozens of cancers at once is being eyed in Congress as a way to detect cancers earlier, minimize the discomfort of cancer treatments and help patients live longer.